Bridging rigorous HEOR methodology with advanced analytics, engineering precision, and innovative technology solutions for healthcare decision-making.
Multidisciplinary expertise at the intersection of health economics, technology, and innovation
Senior Health Economist with 10+ years of experience leading teams in economic modeling, HTA submissions, market access, and pricing strategies across oncology, rare diseases, and cardiometabolic conditions.
Strong analytical expertise combining engineering, statistics, and econometrics with advanced programming skills (R, Python, Julia, VBA, C++). Proven track record in AI integration, blockchain development, and innovative healthcare solutions delivery.
A rare intersection of domains enabling comprehensive understanding of technical, economic, and innovative healthcare challenges.
Worked and studied across Spain, UK, Switzerland, Netherlands, and Belgium, adapting to diverse healthcare systems.
Pioneering AI integration and blockchain development for next-generation healthcare solutions.
Successfully delivered HTA submissions for NICE, NCPE, SMC with major pharmaceutical clients.
Technical skills and domain expertise spanning health economics and advanced technology
Cost-Effectiveness Analysis (CEA), Budget Impact Models (BIM), and health technology assessment submissions for NICE, NCPE, and SMC.
Advanced survival analysis, parametric modeling, and complex statistical evaluations for clinical data interpretation.
Systematic literature reviews and Network Meta-Analysis (NMA) to support value propositions and comparative effectiveness.
Comprehensive pricing strategies, reimbursement dossiers, and value communication tools for global markets.
Full-stack development capabilities applied to health economics modeling and tool creation.
Leveraging AI for process optimization and blockchain for secure, decentralized healthcare solutions.
Comprehensive health economics and outcomes research solutions
Complete HTA submission support for NICE, NCPE, SMC, and other European agencies. Development of evidence-based value dossiers and reimbursement strategies.
Development of sophisticated cost-effectiveness models, budget impact analyses, and dynamic transmission models using state-of-the-art methodologies.
Strategic pricing support and market access planning for pharmaceutical products across multiple markets and therapeutic areas.
Systematic literature reviews, network meta-analyses, and real-world evidence studies to support clinical and economic value propositions.
Integration of artificial intelligence and machine learning to optimize healthcare analytics, automate workflows, and enhance decision-making.
Design and development of user-friendly, interactive tools for payer engagement, scenario analysis, and value demonstration.
Deep knowledge across diverse disease areas
Prostate Cancer, RCC, NSCLC, NETs
Cushing's Syndrome, Sickle Cell Disease
RSV, Infectious Disease Prevention
Rheumatic Diseases, Biologics
Cardiac Devices, PFO Closure
Obesity, Diabetes, CVD
Showcase of innovative health economics work
Visit my GitHub profile to see additional portfolio projects, code repositories, and open-source contributions in health economics, blockchain, and AI integration.
🔗 View GitHub PortfolioJuly 2021 – October 2024
Led development of comprehensive epidemiologic and pharmacoeconomic models for Arexvy (RSV vaccine for older adults) to support global market access strategies.
Collaboration with CHESS
Developed comprehensive static Cost-Effectiveness Model (CEM) and Budget Impact Models (BIM) tailored for multiple country adaptations.
Novartis Oncology, 2020-2021
Developed innovative portfolio approach for Neuroendocrine Tumors allowing flexible pricing strategies across multiple products.
Osilodrostat (LCI699) - Finland Setting
Sophisticated non-homogeneous semi-Markov cohort model to estimate cost-effectiveness of osilodrostat versus other treatments.
Peer-reviewed contributions to health economics literature
Demonstrated the economic value and clinical impact of AKI interventions using a decision tree model, highlighting significant potential cost savings and improved patient outcomes through early detection.
View Article →Adapted a 1-year validated decision-tree model to the UAE setting to estimate cost-effectiveness of long-acting injectable antipsychotics vs. oral treatments, focusing on adherence advantages.
View Article →Career progression in health economics and innovation
Leading innovative projects with Core Obesity Model and integrated Obesity-Diabetes Model, coordinating teams on collaborative initiatives for improved patient outcomes.
Coordinated HTA submissions for NICE, NCPE, SMC. Integrated AI solutions to streamline consultancy processes and improve operational efficiency.
Built comprehensive epidemiologic and pharmacoeconomic models for Arexvy vaccine, developing dynamic transmission models in Excel, VBA, R, and C++.
Supported country affiliates with HTA submissions, developed pricing commercial constructs, and established HEOR Centre of Excellence.
Published research in Kidney International Reports, developed pricing strategy models for Neuroendocrine Tumor treatments across multiple markets.
Academic foundation spanning economics, engineering, and technology
Full Stack, DevOps, Solidity & Hyperledger
Centre for Health Economics - Advanced economic evaluation techniques
With Distinction
Universidad de Navarra - Executive education
Universitat Politècnica de Catalunya + ERASMUS Program
Discuss how I can support your market access goals
Barcelona, Spain
(Remote-Ready)
I design and deliver robust, transparent HEOR models that inform critical pricing and access decisions. By combining deep health economics expertise with advanced analytics and software engineering, I accelerate evidence generation and operational efficiency for global healthcare partners.
Send a Message